Maternal Use of Antacids or Drugs for Gastroesophageal Reflux Diagnosis (GERD) or Stomach Ulcer and Infant Congenital Malformations

  • Bengt Källén


Most previous studies indicate that the use of antacids or drugs for GERD carries no increased risk for infant congenital malformations. This has been verified in the present study with respect to antacids, H2-receptor antagonists, and proton pump inhibitors. Some questions remain concerning the use of sucralfate therapy where a weak teratogenic effect seems to exist. A specific association between use of sucralfate or alginic acid and infant esophageal atresia is suggested but has to be verified in independent studies. The absolute risk is, if existent, negligible.


  1. Anderka M, Mitchell AA, Louik C, Werler MM, Hernández-Diaz S, Rasmussen SA. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res (Pt A). 2012;94:22–30.CrossRefGoogle Scholar
  2. Bánhidy F, Dakhlaoul A, Puhó EH, Czeizel AE. Peptic ulcer disease with related drug treatment in pregnant women and congenital abnormalities in their offspring. Congenit Anom. 2011;51:26–33.CrossRefGoogle Scholar
  3. Colin Jones DG, Langman MJS, Lanson DH, Vessey MP. Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report. Q J Med. 1985;54:253–68.PubMedGoogle Scholar
  4. Diav-Citrin O, Arnon J, Schechtman S, Schaefer C, Van Tonningen MR, Clementi M, De Santis M, Robert-Gnansia E, Valti E, Malm H, Ornoy A. The safety of proton pump inhibitors in pregnancy: a multicenter prospective controlled study. Aliment Pharmacol Ther. 2005;21:269–75.CrossRefGoogle Scholar
  5. Erichsen R, Mikkelsen E, Pedersen L, Sørensen HT. Maternal use of proton pump inhibitors during early pregnancy and the prevalence of hypospadias in male offspring. Am J Ther. 2014;21:254–9.CrossRefGoogle Scholar
  6. Heinonen OP, Sloane D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Science Group, Inc.; 1977.Google Scholar
  7. Källén B. Delivery outcome after the use of acid-suppressive drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynecol. 1998;105:877–81.CrossRefGoogle Scholar
  8. Källén B. Use of omeprazole during pregnancy—no hazard demonstrated in 955 infants exposed during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2001;96:63–8.CrossRefGoogle Scholar
  9. Larkin A, Loebstein R, Addis A, Ramezani-Namin, Mastroiacovo P, Mazzone P, Vial T, Bonati M, Koren G. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol. 1998;179:720–30.Google Scholar
  10. Magee LA, Inocencion G, Kambol L, Rosetti, Koren G. Safety of first trimester exposure to histamine H2 blockers. A prospective cohort study. Dig Dis Sci. 1996;41:1145–9.CrossRefGoogle Scholar
  11. Matok I, Levy A, Wiznitzer A, Uziel E, Koren G, Gorodischer R. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci. 2012;57:699–705.CrossRefGoogle Scholar
  12. Nielsen GL, Sørensen HT, Thulstrup AM, Tage-Jensen U, Olesen C, Ekbom A. The safety of proton pump inhibitors in pregnancy. Aliment Pharmacol Ther. 1999;13:1085–9.CrossRefGoogle Scholar
  13. Pasternak B, Hviid A. Use of proton-pump in early pregnancy and the risk of birth defects. N Engl J Med. 2010;363:2114–23.CrossRefGoogle Scholar
  14. Ruigómez A, Rodriguez AG, Cattaruzzi C, Troncon MG, Agostinis L, Wallander M-A, Johansson S. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcome. Am J Epidemiol. 1999;150:476–81.CrossRefGoogle Scholar
  15. Vauzelle C, Beghin D, Cournot M-P, Elefant E. Birth defects after exposure to misoprostol in the first trimester of pregnancy: prospective follow-up study. Reprod Toxicol. 2013;36:98–103.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Bengt Källén
    • 1
  1. 1.Tornblad Institute for Comparative EmbryologyLund UniversityLundSweden

Personalised recommendations